Your browser doesn't support javascript.
loading
Duodenum-Preserving Pancreatic Head Resection for Benign and Premalignant Tumors-a Systematic Review and Meta-analysis of Surgery-Associated Morbidity.
Beger, Hans G; Mayer, Benjamin; Poch, Bertram.
Afiliação
  • Beger HG; c/o University of Ulm, Albert-Einstein-Allee 23, 89081, Ulm, Germany. hans@beger-ulm.de.
  • Mayer B; Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany. hans@beger-ulm.de.
  • Poch B; Centre for Oncologic, Endocrine and Minimal Invasive Surgery, Donau-Klinikum Neu-Ulm, Neu-Ulm, Germany.
J Gastrointest Surg ; 27(11): 2611-2627, 2023 11.
Article em En | MEDLINE | ID: mdl-37670106
ABSTRACT

BACKGROUND:

Pancreatic benign, cystic, and neuroendocrine neoplasms are increasingly detected and recommended for surgical treatment. In multiorgan resection pancreatoduodenectomy or parenchyma-sparing, local extirpation is a challenge for decision-making regarding surgery-related early and late postoperative morbidity.

METHODS:

PubMed, Embase, and Cochrane Libraries were searched for studies reporting early surgery-related complications following pancreatoduodenectomy (PD) and duodenum-preserving total (DPPHRt) or partial (DPPHRp) pancreatic head resection for benign tumors. Thirty-four cohort studies comprising data from 1099 patients were analyzed. In total, 654 patients underwent DPPHR and 445 patients PD for benign tumors. This review and meta-analysis does not need ethical approval.

RESULTS:

Comparing DPPHRt and PD, the need for blood transfusion (OR 0.20, 95% CI 0.10-0.41, p<0.01), re-intervention for serious surgery-related complications (OR 0.48, 95% CI 0.31-0.73, p<0.001), and re-operation for severe complications (OR 0.50, 95% CI 0.26-0.95, p=0.04) were significantly less frequent following DPPHRt. Pancreatic fistula B+C (19.0 to 15.3%, p=0.99) and biliary fistula (6.3 to 4.3%; p=0.33) were in the same range following PD and DPPHRt. In-hospital mortality after DPPHRt was one of 350 patients (0.28%) and after PD eight of 445 patients (1.79%) (OR 0.32, 95% CI 0.10-1.09, p=0.07). Following DPPHRp, there was no mortality among the 192 patients.

CONCLUSION:

DPPHR for benign pancreatic tumors is associated with significantly fewer surgery-related, serious, and severe postoperative complications and lower in-hospital mortality compared to PD. Tailored use of DPPHRt or DPPHRp contributes to a reduction of surgery-related complications. DPPHR has the potential to replace PD for benign tumors and premalignant cystic and neuroendocrine neoplasms of the pancreatic head.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_endocrine_disorders / 6_pancreatic_cancer Assunto principal: Cisto Pancreático / Neoplasias Pancreáticas / Tumores Neuroendócrinos Tipo de estudo: Observational_studies / Risk_factors_studies / Systematic_reviews Aspecto: Ethics Limite: Humans Idioma: En Revista: J Gastrointest Surg Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Problema de saúde: 6_endocrine_disorders / 6_pancreatic_cancer Assunto principal: Cisto Pancreático / Neoplasias Pancreáticas / Tumores Neuroendócrinos Tipo de estudo: Observational_studies / Risk_factors_studies / Systematic_reviews Aspecto: Ethics Limite: Humans Idioma: En Revista: J Gastrointest Surg Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha
...